Search details
1.
Lower Relapses Rate With Infliximab Versus Adalimumab in Sight-Threatening Uveitis: A Multicenter Study of 330 Patients.
Am J Ophthalmol
; 238: 173-180, 2022 06.
Article
in English
| MEDLINE | ID: mdl-35172172
Results
1 -
1
de 1
1
Next >
>>